EMA Authorised: Cometriq (cabozantinib) — Ipsen Pharma

View source ↗

Summary

Cometriq (cabozantinib) has been authorised in the EU for therapeutic use in thyroid neoplasms by Ipsen Pharma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Neoplasms

Drugs mentioned

• COMETRIQ (CABOZANTINIB)

Snippet

Status: Authorised. Therapeutic area: Thyroid Neoplasms. MAH: Ipsen Pharma. Decision date: 09/07/2026. Orphan medicine